Tanaka KR, Valentine WN, Miwa S. Pyruvate kinase (PK) deficiency hereditary nonspherocytic hemolytic anemia. Blood. 1962;19:267–95.

Article  CAS  PubMed  Google Scholar 

Secrest MH, Storm M, Carrington C, et al. Prevalence of pyruvate kinase deficiency: a systematic literature review. Eur J Haematol. 2020;105(2):173–84.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kung C, Hixon J, Kosinski PA, et al. AG-348 enhances pyruvate kinase activity in red blood cells from patients with pyruvate kinase deficiency. Blood. 2017;130(11):1347–56.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Van Wijk R, Van Solinge WW. The energy-less red blood cell is lost: erythrocyte enzyme abnormalities of glycolysis. Blood. 2005;106(13):4034–42.

Article  PubMed  Google Scholar 

Rab MAE, Van Oirschot BA, Kosinski PA, et al. AG-348 (mitapivat), an allosteric activator of red blood cell pyruvate kinase, increases enzymatic activity, protein stability, and ATP levels over a broad range of PKLR genotypes. Haematologica. 2021;106(1):238–49.

Article  CAS  PubMed  Google Scholar 

Al-Samkari H, van Beers EJ, Kuo KHM, et al. The variable manifestations of disease in pyruvate kinase deficiency and their management. Haematologica. 2020;105(9):2229–39.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Grace RF, Barcellini W. Management of pyruvate kinase deficiency in children and adults. Blood. 2020;136(11):1241–9.

Article  PubMed  Google Scholar 

Grace RF, Bianchi P, van Beers EJ, et al. Clinical spectrum of pyruvate kinase deficiency: data from the pyruvate kinase deficiency natural history study. Blood. 2018;131(20):2183–92.

Article  CAS  PubMed  Google Scholar 

Grace RF, Layton DM, Barcellini W. How we manage patients with pyruvate kinase deficiency. Br J Haematol. 2019;184(5):721–34.

Article  PubMed  Google Scholar 

Higa S, Keapoletswe K, Cirneanu L, et al. P1476: The clinical characteristics and overall survival of patients with pyruvate kinase deficiency in the UK: a real-world study [abstract]. Hemasphere. 2023;7(Suppl): e0113950.

Article  PubMed Central  Google Scholar 

Zagadailov E, Boscoe A, Garcia-Horton V, et al. Mortality among veterans with a diagnosis of pyruvate kinase (PK) deficiency: a real-world study using US veterans health administration data [abstract]. Blood. 2020;136(Supp 1):24–5.

Article  Google Scholar 

US FDA. PYRUKYND (mitapivat) tablets: for oral use: US prescribing information. 2022. https://www.fda.gov. Accessed 13 Oct 2023.

European Medicines Agency. Pyrukynd: EU—summary of product characteristics 2022. https://www.ema.europa.eu. Accessed 13 Oct 2023.

Yang H, Merica E, Chen Y, et al. Phase 1 single- and multiple-ascending-dose randomized studies of the safety, pharmacokinetics, and pharmacodynamics of AG-348, a first-in-class allosteric activator of pyruvate kinase R, in healthy volunteers. Clin Pharmacol Drug Dev. 2019;8(2):246–59.

Article  CAS  PubMed  Google Scholar 

US FDA. PYRUKYND (mitapivat) tablets: integrated review. 2022. https://www.fda.gov. Accessed 13 Oct 2023.

Al-Samkari H, Grace RF, Glenthoej A, et al. Bone mineral density remains stable in pyruvate kinase deficiency patients receiving long-term treatment with mitapivat [abstract]. Blood. 2021;138(Suppl 1):924.

Article  Google Scholar 

Al-Samkari H, Galactéros F, Glenthøj A, et al. Mitapivat versus placebo for pyruvate kinase deficiency. N Engl J Med. 2022;386(15):1432–42.

Article  CAS  PubMed  Google Scholar 

Glenthøj A, van Beers EJ, Al-Samkari H, et al. Mitapivat in adult patients with pyruvate kinase deficiency receiving regular transfusions (ACTIVATE-T): a multicentre, open-label, single-arm, phase 3 trial. Lancet Haematol. 2022;9(10):e724–32.

Article  PubMed  Google Scholar 

Grace RF, Rose C, Layton DM, et al. Safety and efficacy of mitapivat in pyruvate kinase deficiency. N Engl J Med. 2019;381(10):933–44.

Article  CAS  PubMed  Google Scholar 

Egan S, Zagadailov E, Jewett A, et al. Validation of the pyruvate kinase deficiency impact assessment (PKDIA): a patient-reported outcome measure for pyruvate kinase (PK) deficiency [abstract]. Blood. 2021;138(Suppl 1):4145.

Article  Google Scholar 

Egan S, Zagadailov E, Jewett A, et al. Validation of the pyruvate kinase deficiency diary (PKDD): a patient-reported outcome measure for pyruvate kinase (PK) deficiency [abstract]. Blood. 2021;138(Suppl 1):4144.

Article  Google Scholar 

Kuo KHM, Grace RF, van Beers EJ, et al. Long-term improvements in patient-reported outcomes in patients with pyruvate kinase deficiency treated with mitapivat [abstract no. 506 plus presentation]. In: Blood 64th American Society of Hematology Annual Meeting and Exposition (ASH). 2022.

Grace RF, Glenthøj A, Barcellini W, et al. Long-term hemoglobin response and reduction in transfusion burden are maintained in patients with pyruvate kinase deficiency treated with mitapivat [abstract no. 2328 plus poster]. In: Blood 64th American Society of Hematology Annual Meeting and Exposition (ASH). 2022.